The highlights are a good start. (I’m a doctor, just a nerd who likes to read papers.)
My comments in brackets.
- Herpes zoster vaccination reduced dementia diagnosis in our prior natural experiments. [Previous work. I’m familiar with the Wales experiment where they had a sharp age cutoff for getting the vaccine in their national health system. Comparing those just below and just beyond the cutoff allows for analysis similar to a randomized controlled trial (aka ‘natural experiment’). The results showed a ~20% decrease in dementia due to vaccine, so the results were already pretty strong.]
- Here, we find a lower occurrence of MCI and dementia deaths among dementia patients [MCI = ‘mild cognitive impairment’. This is a more refined result than prior work, harder to see in the data than a clear dementia diagnosis.]
- Herpes zoster vaccination appears to act along the entire clinical course of dementia. [This is not surprising given the earlier results, but the demonstration is harder, and it may lead to recommendations for earlier HZ vaccination, IIRC currently at 50 or 55 in the US.]
- This study’s approach avoids the common confounding concerns of observational data [Basically they are improving their methods and getting stronger results, classic good science.]
Months ago when this research was showing up (not on HN) there was a disclaimer that the benefit differed for Shingrix vs Zostavax (discontinued in the United States around 2017), and that Zostavax was shown to cause these benefits (Wales study for example).
It's interesting that the linked article references, in different terms, the distinction, obliquely. Zostavax is attentuated; Shingrix recombinant.
"Our findings suggest that live-attenuated HZ vaccination prevents or delays mild cognitive impairment and dementia and slows the disease course among those already living with dementia."
> Recent studies have shown convincingly that vaccines against shingles (Herpes zoster) reduce the risk of dementia. The shingles vaccine now in widespread use (Shingrix) has more of an effect than the previous one (Zostavax). A key difference between these vaccines is that Shingrix contains an ‘adjuvant’, an ingredient designed to enhance the vaccine’s effect. It is therefore possible that the adjuvant contributes to Shingrix’ greater effect than Zostavax on reducing dementia.
Sorry, I just realized the typo but I can no longer edit: I’m not a doctor, just a nerd. I blame my phone and my own crappy copy-editing. I hope this didn’t confuse too many of you.
My comments in brackets.
- Herpes zoster vaccination reduced dementia diagnosis in our prior natural experiments. [Previous work. I’m familiar with the Wales experiment where they had a sharp age cutoff for getting the vaccine in their national health system. Comparing those just below and just beyond the cutoff allows for analysis similar to a randomized controlled trial (aka ‘natural experiment’). The results showed a ~20% decrease in dementia due to vaccine, so the results were already pretty strong.]
- Here, we find a lower occurrence of MCI and dementia deaths among dementia patients [MCI = ‘mild cognitive impairment’. This is a more refined result than prior work, harder to see in the data than a clear dementia diagnosis.]
- Herpes zoster vaccination appears to act along the entire clinical course of dementia. [This is not surprising given the earlier results, but the demonstration is harder, and it may lead to recommendations for earlier HZ vaccination, IIRC currently at 50 or 55 in the US.]
- This study’s approach avoids the common confounding concerns of observational data [Basically they are improving their methods and getting stronger results, classic good science.]